Submit Manuscript  

Article Details


Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia

[ Vol. 17 , Issue. 8 ]

Author(s):

Alessandro Gozzetti, Veronica Candi, Corrado Zuanelli Brambilla, Giulia Papini, Alberto Fabbri and Monica Bocchia   Pages 1040 - 1045 ( 6 )

Abstract:


Abnormality of the B-cell receptor (BCR) signaling is correlated to origin of many B-cell malignancies. Bruton’s tyrosine kinase (BTK), is described as a possible target in a many B-cell neoplasms. Ibrutinib is the most used inhibitor of BTK and has great tolerability and efficacy in chronic lymphocytic leukemia. This review summarizes results with ibrutinib in clinical trials and novel BTK inhibitors of interest.

Keywords:

CLL, chemotherapy, BTK, BCR, tyrosine, kinase.

Affiliation:

Department of hematology, Azienda Ospedaliera Universitaria Senese, Policlinico S. Maria alle Scotte, viale Bracci 16, 53100 Siena, Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena

Graphical Abstract:



Read Full-Text article